The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.

Inclusion Criteria:

• Subjects aged 18 years or older

• Subjects with a proven diagnosis of Charcot-Marie-Tooth disease type 1 at the timeof screening visit

• Subjects who have muscle weakness in at least foot dorsiflexion (clinicalassessment) at the time of screening visit

• Subjects with a CMT neuropathy score (CMTNS-v2) of 2 or more and 30 or fewer pointsat the time of screening visit

• Subjects who can understand and are willing to sign a written informed consentdocument are willing to comply with all study procedures and schedule visits.

Exclusion Criteria:

• Subjects who have any other neuromuscular diseases

• Subjects who have undergone upper and lower limb bone surgery within six monthsbefore screening visit

• Subjects who have concerns about muscle strength measurements due to the previoussurgery

• Subjects who have severe active infection including severe/purulent cellulitis atthe injection sites at screening visit

• Subjects who have a history of hospitalization due to hypersensitivity toantihistamines or allergy or hypersensitivity to certain substances such as food ordrugs

• Subjects who have a history of unstable cardiovascular disease defined by thepresence of myocardial infarction (STEMI or NSTEMI) within 6 months before thescreening or the presence of unstable angina pectoris (in the case of increasedfrequency of symptoms, increased severity, or signs of prolonged symptoms atmoderate activity or rest)

• Subjects who have a history of a transient ischemic attack (TIA) or stroke within 6months before screening visit

• Subjects who have a positive HIV antibody test, hepatitis B antigen, or hepatitis Cantibody test result

• Subjects who have a history of malignant tumors within 5 years before screeningvisit

• Subjects who have received systemic steroids (inhaled steroids are allowed),immunotherapy, or cytotoxic therapy within 14 days before screening, or who areexpected to receive such treatment during the study period

• Subjects who have participated in other clinical trials within 30 days beforescreening visit

• Pregnant and lactating women or women of childbearing potential and men who plan apregnancy or are unwilling to use adequate birth control methods& until 30 daysafter the end of drug administration